share_log

康希諾生物：自願公告 - 曼海欣藥品補充申請獲得受理

CANSINOBIO: VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE SUPPLEMENTAL DRUG APPLICATION FOR MENHYCIA

HKEX ·  Nov 26 17:28

Summary by Moomoo AI

康希諾生物於2024年11月26日宣布，其曼海欣®腦膜炎球菌多糖結合疫苗（MCV4）的適用年齡範圍擴大申請已獲得國家藥監局受理。此次申請將適用人群從3月齡到3週歲（47月齡）兒童擴大至3月齡到6週歲（83月齡）兒童。這一擴大將進一步提升疫苗的市場覆蓋率。\\n曼海欣®作為我國首個腦膜炎球菌四價結合疫苗，縮小了與發達國家的差距，並填補了國內高端疫苗的空白。該疫苗為嬰幼兒流腦疾病提供了更優的預防方案，並在市場上發揮了獨特的競爭優勢。康希諾生物持續推進流腦疫苗的市場導入，2024年前三季度流腦疫苗產品銷售收入達到5.16億元，同比增長39.07%。\\n康希諾生物董事長Xuefeng YU博士表示，公司將繼續推動流腦疫苗的市場擴展，並致力於提供高質量的疫苗產品。此次年齡範圍的擴大申請獲受理，預示著公司在疫苗研發和市場推廣方面的持續進步。
康希諾生物於2024年11月26日宣布，其曼海欣®腦膜炎球菌多糖結合疫苗（MCV4）的適用年齡範圍擴大申請已獲得國家藥監局受理。此次申請將適用人群從3月齡到3週歲（47月齡）兒童擴大至3月齡到6週歲（83月齡）兒童。這一擴大將進一步提升疫苗的市場覆蓋率。\\n曼海欣®作為我國首個腦膜炎球菌四價結合疫苗，縮小了與發達國家的差距，並填補了國內高端疫苗的空白。該疫苗為嬰幼兒流腦疾病提供了更優的預防方案，並在市場上發揮了獨特的競爭優勢。康希諾生物持續推進流腦疫苗的市場導入，2024年前三季度流腦疫苗產品銷售收入達到5.16億元，同比增長39.07%。\\n康希諾生物董事長Xuefeng YU博士表示，公司將繼續推動流腦疫苗的市場擴展，並致力於提供高質量的疫苗產品。此次年齡範圍的擴大申請獲受理，預示著公司在疫苗研發和市場推廣方面的持續進步。
Cansinobio announced on November 26, 2024, that the application for the expanded age range of its Menhixin® Meningococcal Polysaccharide Conjugate Vaccine (MCV4) has been accepted by the National Medical Products Administration. This application expands the applicable population from children aged 3 months to 3 weeks (47 months old) to children aged 3 months to 6 weeks (83 months old). This expansion will further increase the market coverage of the vaccine. Menhixin® as the first quadrivalent meningococcal conjugate vaccine in China, has narrowed the gap with developed countries and filled the gap in the high-end vaccine market domestically. The vaccine provides a better prevention solution for infantile meningococcal diseases and has shown unique competitive advantages in the market. Cansinobio continues to promote the market introduction of meningococcal vaccines, with...Show More
Cansinobio announced on November 26, 2024, that the application for the expanded age range of its Menhixin® Meningococcal Polysaccharide Conjugate Vaccine (MCV4) has been accepted by the National Medical Products Administration. This application expands the applicable population from children aged 3 months to 3 weeks (47 months old) to children aged 3 months to 6 weeks (83 months old). This expansion will further increase the market coverage of the vaccine. Menhixin® as the first quadrivalent meningococcal conjugate vaccine in China, has narrowed the gap with developed countries and filled the gap in the high-end vaccine market domestically. The vaccine provides a better prevention solution for infantile meningococcal diseases and has shown unique competitive advantages in the market. Cansinobio continues to promote the market introduction of meningococcal vaccines, with sales revenue of meningococcal vaccine products reaching 0.516 billion yuan in the first three quarters of 2024, a year-on-year increase of 39.07%. Dr. Xuefeng YU, the director of cansinobio, stated that the company will continue to promote the market expansion of meningococcal vaccines and is committed to providing high-quality vaccine products. The acceptance of the application for the expanded age range indicates the company's continuous progress in vaccine research and market promotion.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated